Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Integra Lifesciences Holdings Corp (NASDAQ: IART) was $25.42 for the day, down -19.12% from the previous closing price of $31.43. In other words, the price has decreased by -$19.12 from its previous closing price. On the day, 6.08 million shares were traded. IART stock price reached its highest trading level at $27.2 during the session, while it also had its lowest trading level at $22.94.
Ratios:
Our analysis of IART’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.75 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 32.88. For the most recent quarter (mrq), Quick Ratio is recorded 3.35 and its Current Ratio is at 4.68. In the meantime, Its Debt-to-Equity ratio is 1.19 whereas as Long-Term Debt/Eq ratio is at 1.19.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wells Fargo on May 07, 2024, Downgraded its rating to Equal Weight and sets its target price to $25 from $45 previously.
Citigroup Upgraded its Sell to Neutral on April 03, 2024, while the target price for the stock was maintained at $38.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 23 ’24 when ESSIG STUART bought 52,641 shares for $28.49 per share. The transaction valued at 1,499,979 led to the insider holds 487,922 shares of the business.
HILL BARBARA B bought 36,350 shares of IART for $995,816 on May 21 ’24. The Director now owns 36,350 shares after completing the transaction at $27.40 per share. On Mar 06 ’24, another insider, DAVIS ROBERT T. JR., who serves as the EVP & President, TT of the company, sold 8,348 shares for $36.59 each. As a result, the insider received 305,492 and left with 49,893 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IART now has a Market Capitalization of 2003088256 and an Enterprise Value of 3843892480. As of this moment, Integra’s Price-to-Earnings (P/E) ratio for their current fiscal year is 50.15, and their Forward P/E ratio for the next fiscal year is 8.31. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 7.96. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.28 while its Price-to-Book (P/B) ratio in mrq is 1.25. Its current Enterprise Value per Revenue stands at 2.513 whereas that against EBITDA is 10.601.
Stock Price History:
Over the past 52 weeks, IART has reached a high of $46.75, while it has fallen to a 52-week low of $22.36. The 50-Day Moving Average of the stock is -14.29%, while the 200-Day Moving Average is calculated to be -28.76%.
Shares Statistics:
IART traded an average of 1.59M shares per day over the past three months and 1470920 shares per day over the past ten days. A total of 78.17M shares are outstanding, with a floating share count of 66.27M. Insiders hold about 15.91% of the company’s shares, while institutions hold 82.61% stake in the company. Shares short for IART as of 1721001600 were 4127493 with a Short Ratio of 2.59, compared to 1718323200 on 3513482. Therefore, it implies a Short% of Shares Outstanding of 4127493 and a Short% of Float of 6.0599998.
Earnings Estimates
The market rating of Integra Lifesciences Holdings Corp (IART) is currently shaped by the ongoing analysis conducted by 11.0 analysts closely monitoring its performance.On average, analysts expect EPS of $0.62 for the current quarter, with a high estimate of $0.64 and a low estimate of $0.6, while EPS last year was $0.71. The consensus estimate for the next quarter is $0.85, with high estimates of $0.9 and low estimates of $0.83.
Analysts are recommending an EPS of between $3.09 and $3.0 for the fiscal current year, implying an average EPS of $3.04. EPS for the following year is $3.32, with 13.0 analysts recommending between $3.52 and $3.04.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 10 analysts. It ranges from a high estimate of $414.9M to a low estimate of $411.28M. As of the current estimate, Integra Lifesciences Holdings Corp’s year-ago sales were $374.07MFor the next quarter, 10 analysts are estimating revenue of $432.11M. There is a high estimate of $444.4M for the next quarter, whereas the lowest estimate is $411.9M.
A total of 12 analysts have provided revenue estimates for IART’s current fiscal year. The highest revenue estimate was $1.68B, while the lowest revenue estimate was $1.67B, resulting in an average revenue estimate of $1.68B. In the same quarter a year ago, actual revenue was $1.54BBased on 12 analysts’ estimates, the company’s revenue will be $1.77B in the next fiscal year. The high estimate is $1.8B and the low estimate is $1.76B.
